Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
Metrics: PDF 504 views | HTML 864 views | ?
Ling Peng1, Yun Hong2, Xianghua Ye3, Peng Shi4,5, Junyan Zhang6, Yina Wang1 and Qiong Zhao1
1Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
2Department of Pharmacy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
3Department of Radiotherapy, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
4Department of Medical Statistics, Children’s Hospital of Fudan University, Shanghai, China
5Center for Evidence-Based Medicine, Fudan University, Shanghai, China
6Bothwin Clinical Study Consultant, Seattle, WA, USA
Qiong Zhao, email: email@example.com
Keywords: eribulin, peripheral neuropathy, incidence, relative risk, meta-analysis
Received: July 10, 2017 Accepted: August 30, 2017 Published: September 19, 2017
Background: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purpose of this meta-analysis was to determine the overall incidence and RR of eribulin-associated peripheral neuropathy in cancer patients.
Materials and Methods: Pubmed database and Embase and abstracts presented at the American Society of Clinical Oncology (ASCO) meetings were systematically reviewed for primary studies. Eligible studies included prospective clinical trials and expanded access programs of cancer patients treated with eribulin. Statistical analyses were performed to calculate the incidences, RRs, and 95% confidence intervals (CIs).
Results: Altogether, 4,849 patients from 19 clinical trials were selected for this meta-analysis. The incidences of all-grade and high-grade peripheral neuropathy were 27.5% (95% CI: 23.3–32.4%) and 4.7% (95% CI: 3.6–6.2%), respectively. The relative risks of peripheral neuropathy of eribulin compared to control were increased for all-grade (RR = 1.89, 95% CI: 1.10–3.25) but not statistically significant for high-grade (RR = 2.98, 95% CI: 0.71–12.42).
Conclusions: The use of eribulin is associated with an increased incidence of peripheral neuropathy. The RR is increased for all-grade peripheral neuropathy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.